Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of immunotherapy plus targeted therapy combinations in first-line advanced clear cell renal cell carcinoma (MK-3475-U03 substudy 03A)
MOH_2020-11-02_009048Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, lenvatinib, belzutifan, mk-4830, quavonlimab + pembrolizumab and 1 more in clear cell renal cell carcinoma (ccRCC) (5 arms), sponsored by Merck & Co. Primary endpoints: Efficacy and Safety. Started Aug 2020; status: active, not recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on MOH_2020-11-02_009048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-02_009048.